Annual report
9627.TEDINET S100WFSA
Period2024-05-01 → 2025-04-30
Filed2025-07-31
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥456.8bn | 2024-05-01 → 2025-04-30 | Cons. | Net sales |
| Revenue | ¥399.8bn | 2023-05-01 → 2024-04-30 | Cons. | Net sales |
| Revenue | ¥358.7bn | 2022-05-01 → 2023-04-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥316.2bn | 2021-05-01 → 2022-04-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥297.3bn | 2020-05-01 → 2021-04-30d | Cons. | Net sales (5-year summary) |
| Operating income | ¥16.9bn | 2024-05-01 → 2025-04-30 | Cons. | Operating income |
| Operating income | ¥20.4bn | 2023-05-01 → 2024-04-30 | Cons. | Operating income |
| Ordinary income | ¥18.1bn | 2024-05-01 → 2025-04-30 | Cons. | Ordinary income |
| Ordinary income | ¥21.4bn | 2023-05-01 → 2024-04-30 | Cons. | Ordinary income |
| Ordinary income | ¥17.1bn | 2022-05-01 → 2023-04-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.0bn | 2021-05-01 → 2022-04-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥12.6bn | 2020-05-01 → 2021-04-30d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥16.7bn | 2024-05-01 → 2025-04-30 | Cons. | Income before income taxes |
| Profit before tax | ¥19.1bn | 2023-05-01 → 2024-04-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥9.3bn | 2024-05-01 → 2025-04-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥11.4bn | 2023-05-01 → 2024-04-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥9.2bn | 2022-05-01 → 2023-04-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥7.1bn | 2021-05-01 → 2022-04-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.7bn | 2020-05-01 → 2021-04-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥9.3bn | 2024-05-01 → 2025-04-30 | Cons. | Profit loss |
| Net income | ¥11.4bn | 2023-05-01 → 2024-04-30 | Cons. | Profit loss |
| Total assets | ¥311.9bn | at 2025-04-30 | Cons. | Assets |
| Total assets | ¥249.4bn | at 2024-04-30 | Cons. | Assets |
| Total assets | ¥231.8bn | at 2023-04-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥212.5bn | at 2022-04-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥203.7bn | at 2021-04-30d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥169.3bn | at 2025-04-30 | Cons. | Liabilities |
| Total liabilities | ¥114.0bn | at 2024-04-30 | Cons. | Liabilities |
| Net assets / equity | ¥142.6bn | at 2025-04-30 | Cons. | Net assets |
| Net assets / equity | ¥135.4bn | at 2024-04-30 | Cons. | Net assets |
| Net assets / equity | ¥126.5bn | at 2023-04-30v | Cons. | Net assets |
| Net assets / equity | ¥119.0bn | at 2022-04-30v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥115.8bn | at 2021-04-30d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥26.9bn | at 2025-04-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥48.6bn | at 2024-04-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥26.7bn | at 2025-04-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥48.4bn | at 2024-04-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.2bn | at 2023-04-30v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥59.5bn | at 2022-04-30v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥55.0bn | at 2021-04-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥23.1bn | 2024-05-01 → 2025-04-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.0bn | 2023-05-01 → 2024-04-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥20.3bn | 2022-05-01 → 2023-04-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥26.2bn | 2021-05-01 → 2022-04-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥14.9bn | 2020-05-01 → 2021-04-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥65.9bn | 2024-05-01 → 2025-04-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥15.7bn | 2023-05-01 → 2024-04-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥22.3bn | 2022-05-01 → 2023-04-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥13.9bn | 2021-05-01 → 2022-04-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥9.5bn | 2020-05-01 → 2021-04-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥21.1bn | 2024-05-01 → 2025-04-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.1bn | 2023-05-01 → 2024-04-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥11.2bn | 2022-05-01 → 2023-04-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥7.8bn | 2021-05-01 → 2022-04-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥3.6bn | 2020-05-01 → 2021-04-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥264.32 | 2024-05-01 → 2025-04-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥324.64 | 2023-05-01 → 2024-04-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥262.87 | 2022-05-01 → 2023-04-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥201.47 | 2021-05-01 → 2022-04-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥189.04 | 2020-05-01 → 2021-04-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥4,063.53 | at 2025-04-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,866.55 | at 2024-04-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,599.47 | at 2023-04-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,385.51 | at 2022-04-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,267.49 | at 2021-04-30d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 45.7% | at 2025-04-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.3% | at 2024-04-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.6% | at 2023-04-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.0% | at 2022-04-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.8% | at 2021-04-30d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.7% | 2024-05-01 → 2025-04-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.7% | 2023-05-01 → 2024-04-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.5% | 2022-05-01 → 2023-04-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2021-05-01 → 2022-04-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.9% | 2020-05-01 → 2021-04-30d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 13,009 | at 2025-04-30 | Cons. | Number of employees |
| Employees | 11,474 | at 2024-04-30 | Cons. | Number of employees |
| Employees | 10,651 | at 2023-04-30v | Cons. | Number of employees |
| Employees | 9,568 | at 2022-04-30v | Cons. | Number of employees |
| Employees | 9,019 | at 2021-04-30d | Cons. | Number of employees |
| Revenue | ¥17.7bn | 2024-05-01 → 2025-04-30 | Standalone | Operating revenue1 |
| Revenue | ¥14.1bn | 2023-05-01 → 2024-04-30 | Standalone | Operating revenue1 |
| Revenue | ¥12.8bn | 2022-05-01 → 2023-04-30v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥11.5bn | 2021-05-01 → 2022-04-30v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥11.6bn | 2020-05-01 → 2021-04-30d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥7.2bn | 2024-05-01 → 2025-04-30 | Standalone | Operating income |
| Operating income | ¥5.1bn | 2023-05-01 → 2024-04-30 | Standalone | Operating income |
| Ordinary income | ¥7.2bn | 2024-05-01 → 2025-04-30 | Standalone | Ordinary income |
| Ordinary income | ¥5.3bn | 2023-05-01 → 2024-04-30 | Standalone | Ordinary income |
| Ordinary income | ¥5.0bn | 2022-05-01 → 2023-04-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.2bn | 2021-05-01 → 2022-04-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.3bn | 2020-05-01 → 2021-04-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥7.2bn | 2024-05-01 → 2025-04-30 | Standalone | Income before income taxes |
| Profit before tax | ¥5.1bn | 2023-05-01 → 2024-04-30 | Standalone | Income before income taxes |
| Net income | ¥6.9bn | 2024-05-01 → 2025-04-30 | Standalone | Profit loss |
| Net income | ¥4.9bn | 2023-05-01 → 2024-04-30 | Standalone | Profit loss |
| Net income | ¥4.9bn | 2022-05-01 → 2023-04-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥5.0bn | 2021-05-01 → 2022-04-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥6.1bn | 2020-05-01 → 2021-04-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥181.7bn | at 2025-04-30 | Standalone | Assets |
| Total assets | ¥146.2bn | at 2024-04-30 | Standalone | Assets |
| Total assets | ¥143.8bn | at 2023-04-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥140.2bn | at 2022-04-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥136.4bn | at 2021-04-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥93.6bn | at 2025-04-30 | Standalone | Liabilities |
| Total liabilities | ¥62.7bn | at 2024-04-30 | Standalone | Liabilities |
| Net assets / equity | ¥88.1bn | at 2025-04-30 | Standalone | Net assets |
| Net assets / equity | ¥83.5bn | at 2024-04-30 | Standalone | Net assets |
| Net assets / equity | ¥81.3bn | at 2023-04-30v | Standalone | Net assets |
| Net assets / equity | ¥78.2bn | at 2022-04-30v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥77.3bn | at 2021-04-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥9.3bn | at 2025-04-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥34.0bn | at 2024-04-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥197.89 | 2024-05-01 → 2025-04-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥140.65 | 2023-05-01 → 2024-04-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥139.46 | 2022-05-01 → 2023-04-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥141.15 | 2021-05-01 → 2022-04-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥172.16 | 2020-05-01 → 2021-04-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥80 | 2024-05-01 → 2025-04-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥80 | 2023-05-01 → 2024-04-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2022-05-01 → 2023-04-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥55 | 2021-05-01 → 2022-04-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥55 | 2020-05-01 → 2021-04-30d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,512.96 | at 2025-04-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,386.57 | at 2024-04-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,313.07 | at 2023-04-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,227.25 | at 2022-04-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,180.74 | at 2021-04-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 48.5% | at 2025-04-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.1% | at 2024-04-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.5% | at 2023-04-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.8% | at 2022-04-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.6% | at 2021-04-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.1% | 2024-05-01 → 2025-04-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2023-05-01 → 2024-04-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2022-05-01 → 2023-04-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.4% | 2021-05-01 → 2022-04-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.1% | 2020-05-01 → 2021-04-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 35,428,212 | at 2025-04-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,428,212 | at 2024-04-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,428,212 | at 2023-04-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,428,212 | at 2022-04-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 35,428,212 | at 2021-04-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 169 | at 2025-04-30 | Standalone | Number of employees |
| Employees | 162 | at 2024-04-30 | Standalone | Number of employees |
| Employees | 161 | at 2023-04-30v | Standalone | Number of employees |
| Employees | 160 | at 2022-04-30v | Standalone | Number of employees |
| Employees | 156 | at 2021-04-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 66
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | capex | 2024-05-01 → 2025-04-30 | ¥80m |
| Otherother segments | depreciation | 2024-05-01 → 2025-04-30 | ¥318m |
| Otherother segments | revenue | 2024-05-01 → 2025-04-30 | ¥11.0bn |
| Otherother segments | revenue external | 2024-05-01 → 2025-04-30 | ¥11.0bn |
| Otherother segments | revenue intersegment | 2024-05-01 → 2025-04-30 | ¥54m |
| Otherother segments | segment assets | at 2025-04-30 | ¥9.8bn |
| Otherother segments | segment ordinary income | 2024-05-01 → 2025-04-30 | ¥4m |
| Reconciling Itemsreconciling | capex | 2024-05-01 → 2025-04-30 | ¥2.8bn |
| Reconciling Itemsreconciling | depreciation | 2024-05-01 → 2025-04-30 | ¥1.4bn |
| Reconciling Itemsreconciling | revenue | 2024-05-01 → 2025-04-30 | −¥54m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-05-01 → 2025-04-30 | −¥54m |
| Reconciling Itemsreconciling | segment assets | at 2025-04-30 | ¥51.4bn |
| Reconciling Itemsreconciling | segment ordinary income | 2024-05-01 → 2025-04-30 | −¥11.0bn |
| Dispensing Pharmacyreportable segment | capex | 2024-05-01 → 2025-04-30 | ¥7.2bn |
| Dispensing Pharmacyreportable segment | depreciation | 2024-05-01 → 2025-04-30 | ¥4.2bn |
| Dispensing Pharmacyreportable segment | employees | at 2025-04-30 | 11119 pure |
| Dispensing Pharmacyreportable segment | revenue | 2024-05-01 → 2025-04-30 | ¥384.8bn |
| Dispensing Pharmacyreportable segment | revenue external | 2024-05-01 → 2025-04-30 | ¥384.8bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2025-04-30 | ¥216.8bn |
| Dispensing Pharmacyreportable segment | segment ordinary income | 2024-05-01 → 2025-04-30 | ¥24.3bn |
| Drug And Cosmetic Storereportable segment | capex | 2024-05-01 → 2025-04-30 | ¥2.4bn |
| Drug And Cosmetic Storereportable segment | depreciation | 2024-05-01 → 2025-04-30 | ¥1.3bn |
| Drug And Cosmetic Storereportable segment | employees | at 2025-04-30 | 1231 pure |
| Drug And Cosmetic Storereportable segment | revenue | 2024-05-01 → 2025-04-30 | ¥61.0bn |
| Drug And Cosmetic Storereportable segment | revenue external | 2024-05-01 → 2025-04-30 | ¥61.0bn |
| Drug And Cosmetic Storereportable segment | segment assets | at 2025-04-30 | ¥34.0bn |
| Drug And Cosmetic Storereportable segment | segment ordinary income | 2024-05-01 → 2025-04-30 | ¥4.8bn |
| —segment total | capex | 2024-05-01 → 2025-04-30 | ¥9.7bn |
| —segment total | depreciation | 2024-05-01 → 2025-04-30 | ¥5.9bn |
| —segment total | revenue | 2024-05-01 → 2025-04-30 | ¥456.9bn |
| —segment total | revenue external | 2024-05-01 → 2025-04-30 | ¥456.8bn |
| —segment total | revenue intersegment | 2024-05-01 → 2025-04-30 | ¥54m |
| —segment total | segment assets | at 2025-04-30 | ¥260.5bn |
| —segment total | segment ordinary income | 2024-05-01 → 2025-04-30 | ¥29.1bn |
| Otherother segments | capex | 2023-05-01 → 2024-04-30 | ¥1.0bn |
| Otherother segments | depreciation | 2023-05-01 → 2024-04-30 | ¥279m |
| Otherother segments | revenue | 2023-05-01 → 2024-04-30 | ¥11.2bn |
| Otherother segments | revenue external | 2023-05-01 → 2024-04-30 | ¥11.1bn |
| Otherother segments | revenue intersegment | 2023-05-01 → 2024-04-30 | ¥54m |
| Otherother segments | segment assets | at 2024-04-30 | ¥10.4bn |
| Otherother segments | segment ordinary income | 2023-05-01 → 2024-04-30 | ¥47m |
| Reconciling Itemsreconciling | capex | 2023-05-01 → 2024-04-30 | ¥2.3bn |
| Reconciling Itemsreconciling | depreciation | 2023-05-01 → 2024-04-30 | ¥1.0bn |
| Reconciling Itemsreconciling | revenue | 2023-05-01 → 2024-04-30 | −¥54m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-05-01 → 2024-04-30 | −¥54m |
| Reconciling Itemsreconciling | segment assets | at 2024-04-30 | ¥3.9bn |
| Reconciling Itemsreconciling | segment ordinary income | 2023-05-01 → 2024-04-30 | −¥9.4bn |
| Dispensing Pharmacyreportable segment | capex | 2023-05-01 → 2024-04-30 | ¥8.0bn |
| Dispensing Pharmacyreportable segment | depreciation | 2023-05-01 → 2024-04-30 | ¥3.7bn |
| Dispensing Pharmacyreportable segment | revenue | 2023-05-01 → 2024-04-30 | ¥357.6bn |
| Dispensing Pharmacyreportable segment | revenue external | 2023-05-01 → 2024-04-30 | ¥357.6bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2024-04-30 | ¥219.7bn |
| Dispensing Pharmacyreportable segment | segment ordinary income | 2023-05-01 → 2024-04-30 | ¥27.6bn |
| Drug And Cosmetic Storereportable segment | capex | 2023-05-01 → 2024-04-30 | ¥1.4bn |
| Drug And Cosmetic Storereportable segment | depreciation | 2023-05-01 → 2024-04-30 | ¥438m |
| Drug And Cosmetic Storereportable segment | revenue | 2023-05-01 → 2024-04-30 | ¥31.1bn |
| Drug And Cosmetic Storereportable segment | revenue external | 2023-05-01 → 2024-04-30 | ¥31.1bn |
| Drug And Cosmetic Storereportable segment | segment assets | at 2024-04-30 | ¥15.4bn |
| Drug And Cosmetic Storereportable segment | segment ordinary income | 2023-05-01 → 2024-04-30 | ¥3.1bn |
| —segment total | capex | 2023-05-01 → 2024-04-30 | ¥10.5bn |
| —segment total | depreciation | 2023-05-01 → 2024-04-30 | ¥4.4bn |
| —segment total | revenue | 2023-05-01 → 2024-04-30 | ¥399.9bn |
| —segment total | revenue external | 2023-05-01 → 2024-04-30 | ¥399.8bn |
| —segment total | revenue intersegment | 2023-05-01 → 2024-04-30 | ¥54m |
| —segment total | segment assets | at 2024-04-30 | ¥245.5bn |
| —segment total | segment ordinary income | 2023-05-01 → 2024-04-30 | ¥30.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,668
| Item | Context | Value | Unit |
|---|---|---|---|
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 5 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 7.9 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 80 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 74.3 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 40 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | 100 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row5Member | 100 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 40.6 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | 98.1 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row5Member | 56.7 | |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 17234000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E04896-000DispensingPharmacyReportableSegmentsMember | 11181000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E04896-000DrugAndCosmeticStoreReportableSegmentsMember | 2950000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 35428212 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 35428212 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 35428212 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 35428212 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 27 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 19 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 181 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 200 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 60 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 17776 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 18263 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 96772 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 14695 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 39461 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 125235 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 88 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 77835 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 354086 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 19612 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.2733 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0415 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.1114 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.3537 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0002 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.2198 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 3240000 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.0917 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 2750000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.0778 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 2633000 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0745 | |
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 2528000 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.0716 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |